Article info

Download PDFPDF
Review
Rituximab in AChR subtype of myasthenia gravis: systematic review

Authors

  • Vincenzo Di Stefano Department of Biomedicine, Neuroscience and advanced Diagnostic, University of Palermo, Palermo, Sicily, Italy Department of Neuroscience Imaging and Clinical Sciences, Gabriele d'Annunzio University of Chieti and Pescara, Chieti, Abruzzo, Italy PubMed articlesGoogle scholar articles
  • Antonino Lupica Department of Clinical and Experimental Medicine, Unit of Neurology and Neuromuscular Disease, University of Messina, Messina, Sicilia, Italy PubMed articlesGoogle scholar articles
  • Marianna Gabriella Rispoli Department of Neuroscience Imaging and Clinical Sciences, Gabriele d'Annunzio University of Chieti and Pescara, Chieti, Abruzzo, Italy PubMed articlesGoogle scholar articles
  • Antonio Di Muzio Department of Neurology, SS Annunziata Hospital, Chieti, Abruzzo, Italy PubMed articlesGoogle scholar articles
  • Filippo Brighina Department of Biomedicine, Neuroscience and advanced Diagnostic, University of Palermo, Palermo, Sicily, Italy PubMed articlesGoogle scholar articles
  • Carmelo Rodolico Department of Clinical and Experimental Medicine, Unit of Neurology and Neuromuscular Disease, University of Messina, Messina, Sicilia, Italy PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Vincenzo Di Stefano, Department of Biomedicine, Neuroscience and advanced Diagnostic, University of Palermo, Palermo, Sicily, Italy; vincenzo19689{at}gmail.com
View Full Text

Citation

Di Stefano V, Lupica A, Rispoli MG, et al
Rituximab in AChR subtype of myasthenia gravis: systematic review

Publication history

  • Received December 10, 2019
  • Revised February 4, 2020
  • Accepted February 5, 2020
  • First published February 25, 2020.
Online issue publication 
March 16, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.